Reviewers

Therapeutics

Takashi Kiyoizumi, MD, PhD, SM​

米国サンディエゴ在住のエンジェル投資家・起業家。認定形成外科医として医療に従事した後に渡米。複数のボストンの医薬品ベンチャーにて事業開発・戦略企画担当の副社長を歴任した後、田辺三菱製薬の米国法人の社長に就任。2001年にはMediciNova, Inc.をスピンオフにより創立しCEOを務め、2005年に株式上場させた。
  • M.D. and Ph.D. from Keio University School of Medicine
  • MBA from Sloan School of Management at MIT

水井 佳治 Ph.D.​​

President of Eisai Innovation, Inc. & Head of Cambridge office

20年超に亘り創薬研究に携わる。2019年より米国Bostonに設立されたEisai Innovationの代表。それ以前は、エーザイ(株)オンコロジービジネスグループのストラテジー部長(兼)戦略推進グループ長。また2016年まではがん治療薬の創出・開発を目的に米国Massachusetts州Cambridgeに設立されたH3 Biomedicineの創設メンバーとしてがん治療薬開発をリードした。
  • 九州大学大学院農学部農芸化学科修士課程修了(農学博士)

宮下 定一​​

エーザイ (株) コーポレートベンチャーインベストメント部, ディレクター

エーザイ入社後、15年に亘り創薬研究と共に戦略立案に携わる。その後米国Massachusetts州Andoverに設立されたAndover Innovative medicines Instituteにて、ポートフォリオ・マネジメント長として、プログラムの戦略・管理や社外連携を担当。帰国後、コーポレートストラテジー・事業開発部を経て、2019年より現部署。
  • 岐阜薬科大学大学院分子生物学修士課程修了

森 文隆 Ph.D.

大鵬イノベーションズ, パートナー

2003年、大鵬薬品に入社し、創薬研究に従事。その後、創薬企画部門にて、シーズ探索や創薬基盤構築のため大学やベンチャー企業との共同研究推進、アーリーステージアセットの導入評価、ポートフォリオ戦略策定をリード。15年にRemiges Ventures(独立系VC)に出向。米国Bostonを拠点に創薬ベンチャー投資を担当。2019年、大鵬イノベーションズ設立と同時に同社パートナーに就任。
  • 静岡県立大学大学院薬学研究科修了(薬学博士)

Medical Devices

鈴木 貞史​

40年超のビジネスキャリアを通して、ヘルスケア・ライフサイエンスビジネスにおける国内外での企業経営を経験。協和発酵、Baxter、日本Alconの他、Affymetrix Japan、Bio-Rad Laboratories、Cepheidでは日本法人代表を務める。医薬品、医療機器、臨床診断機器試薬、研究支援ツールなどに関連する内外市場展開の豊富な経験を有する。現在、ベルギー本拠のVC、Newton Biocapital の日本代表。
  • MBA from Kellogg School at Northwestern Univ.

Zachary Burkett

Mr. Zachary Burkett is a Medical Device Distributor based in New Mexico who has been in the industry for 18 years. He has 30 employees spread out over the Southwest focused on Operative and Non-Operative technologies for a broad range of specialties including Spine, Neurosurgery, Orthopedics, OMF, CardioThoracic, Critical Care and Pediatrics. He gets the pleasure of seeing many people engaged in the delivery of health care that improves the lives of many and see firsthand their challenges in providing more.

Clinical

  • Abdominal

David W. Dietz, MD

David W. Dietz, MD is Chief of Colorectal Surgery at University Hospitals Cleveland Medical Center, Vice President of System Surgery Quality at University Hospitals, and Professor of Surgery at Case Western Reserve University School of Medicine. He is a graduate of Jefferson Medical College and completed both General Surgery Residency and Colorectal Surgery Fellowship at Cleveland Clinic. Dr. Dietz’s main clinical interests are reoperative abdominal and pelvic surgery, redo pelvic pouch surgery, locally-advanced and recurrent rectal cancer, and continent ileostomy surgery. He is a founder and member of the Executive Committee of the National Accreditation Program for Rectal Cancer (NAPRC).

Finance

Takuma Aoyama, MBA

Mr. Aoyama is the founder of AIFAM Group, a global investment management company. AIFAM currently manages $700 million in on a discretionary basis. Mr. Aoyama is responsible for overall investment strategy across hedge funds to private equity and venture capital. Prior to founding AIFAM, Mr. Aoyama was at UBS Global Asset Management in Chicago and Long-Term Credit Bank of Japan.
  • MBA from University of Chicago

From VCs

Justin Klein, MD, JD

Justin Klein, MD, JD is a co-founder and Managing Partner at Vensana Capital. Justin was previously a partner and leader of the medical technology investing practice at NEA, one of the largest and most active venture capital firms in the world. Justin also worked at the Duke University Health System where his experience included roles in strategy, finance and operations as Duke built one of the nation’s first integrated healthcare delivery systems. Justin currently serves as a member of the Board of Directors of the Medical Device Manufacturers Association and that of AdvaMed Accel, where he is the Chair of its MedTech Investment Working Group. Justin graduated with an AB in Economics, a BS in Biological Anthropology & Anatomy, and a Minor in Chemistry from Duke University. He also concurrently earned his MD from the Duke University School of Medicine and his JD from Harvard Law School.

Marc Martin-Casas, PhD

Marc joined Illumina Accelerator in 2019, where he manages seed investments and venture development in the genomic and precision medicine spaces. Previously, Marc led Biotech Connection – Bay Area, an incorporated nonprofit that accelerates innovation and development for biotech startups and big pharma by bringing together academic scientists, entrepreneurs, and investors. Prior to that, Marc was on the investment team at Lam Research Capital, where he sourced and performed diligence on life science investment opportunities. Marc earned his Ph.D. in Computational Biology from the University of California, Berkeley, where he focused on the development of novel tools to characterize, model, and predict heterogeneous behavior in cell populations and other complex biochemical systems.